Racura Oncology Limited (ASX:RAC) has disclosed that Sheba Medical Center's Institutional Helsinki Committee approved the EMILI clinical trial on 18 November 2026, with the Israeli Ministry of Health confirming no separate approval is required, moving the seamless Phase 2b/3 study of RC220 in relapsed or refractory acute myeloid leukaemia closer to its first patient enrolment.
Key Points
- Sheba Medical Center's Institutional Helsinki Committee approved the EMILI trial on 18 November 2026, with only minor consent-form updates and no design changes
- Israeli Ministry of Health confirmed no separate approval is required for the EMILI trial
- Institutional governance review at Sheba is underway and described as well advanced, with site activation expected by end of 2026
- First patient enrolment is estimated for Q1 2027, with first human MYC target engagement data expected after 12–18 patients
- Additional sites in Europe, the United States and Australia are planned to open in 2027, subject to required regulatory approvals, ethics clearances and site feasibility
EMILI Trial Design and Principal Investigator
The EMILI trial — Evaluation of a MYC-silencing Intervention in Acute Myeloid LeukemIa — is a seamless Phase 2b/3 clinical trial evaluating RC220, described as an investigational formulation of (E,E)-bisantrene, in patients with relapsed or refractory acute myeloid leukaemia. The Phase 2b stage is designed to enrol up to 68 patients. Professor Arnon Nagler of Sheba Medical Center, Israel, has been named as the principal investigator. The trial's clinical question is whether a single seven-day course of RC220 can bring patients with relapsed or refractory acute myeloid leukaemia into remission and eligibility for allogeneic stem cell transplant.
Sheba Site Activation and Enrolment Timeline
Following receipt of ethics approval, Sheba Medical Center's institutional governance review is stated to be underway and well advanced. According to the company's disclosure, site activation at Sheba is expected by the end of 2026, subject to completion of institutional governance approval and protocol training. First patient enrolment is estimated for Q1 2027. The filing notes that all timelines are estimates and subject to change. First human MYC target engagement data is expected following enrolment of 12 to 18 patients.
Global Site Expansion Plans for 2027
Racura Oncology disclosed plans to expand the EMILI trial to additional clinical sites in Europe, the United States and Australia, with these sites planned to open in 2027. The company stated that opening of these additional sites is subject to required regulatory approvals, ethics clearances and site feasibility. The filing notes that RC220 has not been approved by any regulatory authority in any jurisdiction, and that preclinical findings and historical RC110 results do not predict the outcome of the EMILI trial. The company presented the update at an investor webinar on 19 November 2026.



Please wait processing your request...